New fixed dose chemical combinations: the way forward for better diabetes type II management?

References

• Global report on diabetes. Geneva: World Health Organization; 2016. [Cited 2016 July 22]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.
   Google Scholar
• International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.
   Google Scholar
• Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Blonde L, Juan ZTS, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract. 2014;20:1322–1332.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Efficacy and safety of jentadueto® (linagliptin plus metformin). Expert Opin Drug Saf. 2013;12:275–289.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016 Jul 29:1–11. [ Epub ahead of print].
   PubMedGoogle Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) group. Jama. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535–1540.
   PubMed Web of Science ®Google Scholar
• Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27:1102–1110.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Kollaki C, Doupis J. Linagliptin/metformin fixed –dose combination treatment: a dual attack to type 2 diabetes pathophysiology. Adv Ther. 2012;29:993–1004.
   PubMed Web of Science ®Google Scholar
• Haak T. Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clin Med Insights: Endocrinol Diabetes. 2015;8:1–6.
   PubMedGoogle Scholar
• Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122:71–80.
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168.
   PubMed Web of Science ®Google Scholar
• Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460–467.
   PubMed Web of Science ®Google Scholar
• Vittorino Gaddi A, Benedetto D, Capello F, et al. Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens. Public Health. 2014;128:70–76.
   PubMed Web of Science ®Google Scholar
• Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas medicaid recipients. Clin Ther. 2008;30:1893–1907.
   PubMed Web of Science ®Google Scholar
• (5)SYNJARDY® (empagliflozin and metformin hydrochloride) tablets. Highlights of prescribing information. [ Cited 2016 Jul 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206111lbl.pdf.
   Google Scholar
• Häring H, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396–3404.
   PubMed Web of Science ®Google Scholar
• Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–158.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 2010;375:2223–2233.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:193.
   Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022.
   PubMed Web of Science ®Google Scholar
• Triplitt CL. Understanding the kidneys’ role in blood glucose regulation. Am J Manag Care. 2012;18(1 Suppl):S11–S16.
   Google Scholar
• Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. U.S. FDA approves invokamet (canagliflozin/metformin hCl) for the treatment of adults with type 2 diabetes: in phase 3 studies, invokana plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone. Press Release. 2014 Aug 8. [Cited 2016 Jun 20]. Available from: www.investor.jnj.com/releasedetail.cfm?releaseid=865927.
   Google Scholar
• Invokamet (canagliflozin and metformin hydrochloride) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; Jun 2016. [Cited 2016 July 23]. Available from: https://www.invokamet.com/about-invokamet/what-is-invokamet.
   Google Scholar
• Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382:941–950.
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs. 2011;71:1441–1467.
   PubMed Web of Science ®Google Scholar
• Nesina (alogliptin), prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; Jun 2013. [Cited 2016 July 23] Available from: https://www.nesinafamily.com/nesina/
   Google Scholar
• Dineen L, Law C, Scher R, et al. Alogliptin (nesina) for adults with type-2 diabetes. Pharm Ther. 2014;39:186.
   Google Scholar
• Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study. Int J Clin Pract. 2009;63:46–55.
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type-2 diabetes. J Clin Endocrinol Metab. 2012;97:1615–1622.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:48–56.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. JENTADUETO (linagliptin and metformin) tablets. Summary of product characteristics. 2014. [Cited 2016 Jul 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002279/human_med_001574.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetes patients. J Clin Endocrinol Metab. 2007;92:1249–1255.
   PubMed Web of Science ®Google Scholar
• Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103–109.
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic -cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105.
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51:2796–2803.
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in hispanic women with prior gestational diabetes. Diabetes. 2006;55:517–522.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166–174.
   PubMed Web of Science ®Google Scholar
• Pratley R, Reusch J, Fleck P, et al. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes (abstract). Diabetes. 2008;57(Suppl 1):A143.
   Google Scholar
• Eli Lilly and Company. U.S. FDA approves first-in-class glyxambi (empagliflozin/linagliptin) tablets for adults with type 2 diabetes. Press Release. 2015 Feb 2. [Cited 2016 Jul 24]. Available from: http://lilly.mediaroom.com/index.php?s=9042&item=137386.
   Google Scholar
• Glyxambi (empagliflozin and linagliptin) tablets [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Jan 2015.
   Google Scholar
• DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Glyxambi (empagliflozin/linagliptin): a dual- acting oral medication approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015;8:171–175.
   PubMedGoogle Scholar
• Rendell M. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. Drugs Today (Barc). 2015;51:185–196.
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsbøll T, Thurman J, et al. NN9068-3912 (DUAL-II) trial investigators. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (iDegLira). Diabetes Care. 2014;37:2926–2933.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (iDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–893.
   PubMed Web of Science ®Google Scholar
• Kumar A. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther. 2014;14:869–878.
   PubMed Web of Science ®Google Scholar
• Simpson R, King A. Can a fixed-ratio combination of insulin degludec and liraglutide help type 2 diabetes patients to optimize glycemic control across the day? Expert Rev Clin Pharmacol. 2015;8:179–188.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74.
   PubMed Web of Science ®Google Scholar